Authors
Shmelkova M.S., Serova N.K., Eliseeva N.M., Tropinskaya O.F., Poddubsky A.A., Kobyakov G.L., Vetlova E.R., Zolotova S.V., Golanov A.V.
Burdenko National Medical Research Center of Neurosurgery, Moscow
Abstract
Purpose. The purpose of this study was to compare the clinical outcomes, toxicity profiles, and local control rates between patients receiving a total dose of 40 Gy with dose per fraction of 2 Gy and those receiving a total dose of 45 Gy with dose per fraction of 1,8 Gy, in order to determine the optimal dose/fractionating plan in patients with vitreoretinal lymphoma.
Methods. This retrospective comparative study included 31 patients with molecularly confirmed vitreoretinal lymphoma (VRL) treated with external beam radiation therapy (EBRT) between 2012 and 2025. Patients were divided into two groups according to total radiation dose: Group A (n = 16) received 40 Gy in 22 fractions of 1.8 Gy, and Group B (n = 15) received 45 Gy in 25 fractions of 1.8 Gy. Local toxicity (periorbital dermatitis, radiation xerophthalmia, keratitis, radiation retinopathy and optic neuropathy) as well as local tumour control (vitreous haze relapse) were evaluated at 1,5 months, 6 months and 12 months follow ups after the EBRT.
Results. A total of 31 patients (53 eyes) were analyzed across two group. In Group A (15 patients, 26 eyes), dermatitis was the most common acute complication at 1 month follow up (84.6%), followed by dry eye (65.4%) and keratitis (38.5%). By 6 months, dry eye persisted in 46.2% and keratitis in 19.2%, while dermatitis declined to 3.8%. At 12 months, dermatitis and dry eye resolved completely (0%), but vitreous haze relapses increased to 38.5% and retinopathy emerged in 7.7%. In Group B (16 patients, 27 eyes), dermatitis occurred in 57.7% at 1 month, dry eye in 57.7%, and keratitis in 11.5%. At 6 months, dry eye decreased to 19.2% and keratitis to 7.7%.
At 12 months, only 3.8% had vitreous changes and no cases of dermatitis, dry eye, keratitis, or retinopathy were observed. Neuropathy was absent in both cohorts at all time points.
Conclusion. In this study radiation therapy the plan of a total dose of 45 Gy with dose per fraction of 1,8 Gy demonstrated superior tumor control outcomes and a more favorable local toxicity profile compared to the plan of a total dose of 40 Gy with dose per fraction of 2,0 Gy. Patients treated with the 45 Gy regimen achieved higher rates of local control and prolonged progression-free survival, while experiencing fewer radiation-related ocular complications, including radiation retinopathy, optic neuropathy, dry eye syndrome and keratitis.
Keywords: vitreoretinal lymphoma, stereotactic radiotherapy, local control, radiation-induced ocular toxicity, hypofractionation.
References
1. Zhang Y, Zhou DB. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment. Chin Med J. 2020; 133(12): 1462-1469. doi: 10.1097/CM9.0000000000000844.
2. Cioboată ML, Tofolean I, Abduraman S, et al. Diagnostic and therapeutic challenges in primary vitreoretinal lymphoma: a practical clinical approach. Rom J Ophthalmol. 2026; 70(2): 204-215. doi: 10.22336/rjo.2026.29.
3. Soussain C, Malaise D, Cassoux N. Primary vitreoretinal lymphoma: a diagnostic and management challenge. Blood. 2021; 138(17): 1519-1534. doi: 10.1182/blood.2020008235/
4. Huang RS, Mihalache A, Popovic MM, et al. Diagnostic methods for primary vitreoretinal lymphoma: A systematic review. Surv Ophthalmol. 2024; 69(3): 456–464. doi: 10.1016/j.survophthal.2023.12.001.
5. Menean M, Giuffrè C, Cicinelli MV, et al. A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma. Eur J Ophthalmol. 2024; 34(4): 931-940. doi: 10.1177/11206721231211931.
6. Ostrovsky M, Sela TC, Habot-Wilner Z. Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and meta-analysis. Clin Exp Ophthalmol. 2025; 53(1): 84-99. doi: 10.1111/ceo.14443.
7. Leeson S, Jayamohan J, Vu H, Sundaresan P. Examining the utility of lower dose radiotherapy for localised primary ocular adnexal MALT lymphoma. J Med Radiat Sci. 2021; 68(3): 269-273. doi: 10.1002/jmrs.464.
8. Lesueur P, Damaj G, Hoang-Xuan K, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: an LOC network study. Blood Adv. 2022; 6(16): 4807-4815. doi: 10.1182/bloodadvances.2022007011.
9. Bessell EM, Graus F, López-Guillermo A, et al. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 2001; 50(2): 457-464.


